We adhere to investing in early-stage, small-scale, long-term and hard-tech projects, give priority to cutting-edge technologies in areas like new-generation IT, medicine and healthcare, new energy, new materials and high-end manufacturing. We provide "patient capital" supporting technology enterprises through their development cycles.

Our fund product line includes: mother funds, scientist funds, cuting-edge technology VC funds, debt-like equity funds, cuting-edge technology PE funds, merger and acquisition funds, strategic funds, S funds, overseas funds.

Up to date, the Group manages 57 funds, including 47 direct investment funds and 10 mother funds. The Group totally manages funds of 55.7 billion yuan and invests in 4,000 projects. Notable investments include SMIC North, GigaDevice, NAURA, UNISOC, GRINM NCS Testing Technology, BeiGene, and TINAVI Medical Technologies, and etc.